{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T02:19:56Z","timestamp":1715998796662},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1001\/jamaoncol.2018.0186","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T16:31:08Z","timestamp":1523550668000},"page":"1118","source":"Crossref","is-referenced-by-count":8,"title":["Hypopigmented Skin Lesions After Immunotherapy"],"prefix":"10.1001","volume":"4","author":[{"given":"Ecaterina Ileana","family":"Dumbrava","sequence":"first","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doina","family":"Ivan","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"key":"ccg180001r1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review.","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"31","key":"ccg180001r2","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors.","volume":"33","author":"Chiou","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9988","key":"ccg180001r3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo.","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"ccg180001r4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/jde.2017.44.issue-2","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study.","volume":"44","author":"Nakamura","year":"2017","journal-title":"J Dermatol"},{"issue":"1","key":"ccg180001r5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab.","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"2","key":"ccg180001r6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jdcr.2016.10.008","article-title":"Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: a novel finding.","volume":"3","author":"Yin","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"3","key":"ccg180001r7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1001\/archderm.1995.01690150078015","article-title":"Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.","volume":"131","author":"Cui","year":"1995","journal-title":"Arch Dermatol"},{"issue":"6","key":"ccg180001r8","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1046\/j.1523-1747.1998.00411.x","article-title":"Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.","volume":"111","author":"Okamoto","year":"1998","journal-title":"J Invest Dermatol"},{"issue":"7","key":"ccg180001r9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma.","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"ccg180001r10","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2678089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T19:58:49Z","timestamp":1533844729000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.0186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.0186","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8,1]]}}}